WebBackground: Previous locoregional treatment could affect the response to nivolumab in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The aim of this study is to evaluate the impact of the clinicopathological characteristics and previous treatment in predicting early progression to nivolumab in a … WebFeb 27, 2024 · Female gender is one of the biggest risk factors for recurring and refractory UTIs because of the anatomic make-up of the female genitourinary tract. Aging is also another risk factor. “Aging predisposes women to a number of changes in the vaginal environment, such as vaginal atrophy due to a decrease in estrogen production that leads …
Frontiers Mesenchymal stromal cell therapy for feline chronic ...
WebWhen this happens, it’s called recurrent or relapsed. If it doesn’t respond to treatment or comes back within 60 days after your last therapy, it’s known as refractory. You’ll probably ... WebRefractory periodontal disease is characterized by low plaque scores and low responsiveness to periodontal therapy. The patients often have a history of antibiotic … triethylammonium carbadodecaborate
Adding Ipilimumab to Nivolumab Provides No Benefit in Recurrent …
WebSep 22, 2016 · The optimal dose of rituximab for ITP treatment has not been established. We use 375 mg/m 2 once per week × 4 weeks, but lower doses may be effective ( Table 2 ). 20 Rituximab is generally well tolerated. Toxicities include infusion reactions, serum sickness, and prolonged immune suppression. WebThe term recurrent periodontitis is used to indicate a return of periodontitis and not a separate disease. Potentially, any patient with a past history of periodontitis can develop recurrent periodontitis if adequate oral hygiene is not maintained. Accumulation of dental plaque due to poor oral hygiene or lack of routine periodontal debridement WebJan 10, 2024 · For refractory disease (no initial response) or resistant relapse (disease-free interval less than three months from the last day of initial treatment), most agents or … terrence riesch